問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

Linkou Chang Gung Medical Foundation

Recruiting

List

917Cases

2019-01-01 - 2023-12-31

Others

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2020-01-01 - 2023-12-31

Phase II

Image characteristic and longitudinal follow up of 18F-PMPBB3 (APN-1607) PET for Progressive Supranuclear Palsy

  • Condition/Disease

    Progressive Supranuclear Palsy

  • Test Drug

    18F-PMPBB3 (別名APN-1607, MNI-958, or APN-0000455)

Participate Sites
1Sites

Recruiting1Sites

2017-01-01 - 2019-12-31

Others

Molecular PET/MR imaging in vivo validation of biomarker for human prostate cancer

  • Condition/Disease

    Prostate Adenocarcinoma

  • Test Drug

    [11C]Choline ([11C]Methyl-dimethyl-2-hydroxyethyl-ammonium), Glass vial with 40-331mCi of 11C choline in aqueous 0.9% sodium

Participate Sites
1Sites

Recruiting1Sites

2016-07-01 - 2023-05-09

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2017-08-01 - 2021-12-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2017-08-01 - 2023-12-01

Others

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

2021-06-30 - 2023-12-31

Phase II

An open-label, comparative phase II clinical trial to assess the accuracy and reliability of the Ga68-Dolacga positron emission tomography compared to computer tomography volumetry and indocyanine green retention test for measurement of liver reserve among scheduled surgery operation patients

  • Condition/Disease

    Hepatic Carcinoma

  • Test Drug

    Dolacga (Lyophilized product for the preparation of gallium Ga68-Dolacga injection)

Participate Sites
1Sites

Recruiting1Sites

2020-05-18 - 2023-12-31

Others

Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (aducanumab) in Subjects With Alzheimer’s Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302, and 221AD205

  • Condition/Disease

    Alzheimer's Disease

  • Test Drug

    Aducanumab

Participate Sites
5Sites

Not yet recruiting3Sites

Recruiting2Sites

2020-08-01 - 2023-11-23

Phase I/II

A Phase 1/2, Open-Label, Dose-Escalation And Expansion Study Of Entrectinib (Rxdx-101) In Pediatrics With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

  • Condition/Disease

    Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options

  • Test Drug

    ENTRECTINIB (RXDX-101)

Participate Sites
2Sites

Recruiting2Sites

2021-03-17 - 2025-06-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

1 83 84 85 86 87 92
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB